Medications to Manage Acne on AndroGel (testosterone topical): First-Line and Beyond

At a glance

| Parameter | Detail | |---|---| | Reported incidence (AndroGel 1% trial) | Acne in 3-8% of patients in key phase III data; higher rates in younger men and those titrated to supraphysiologic DHT levels | | Typical onset | 4-12 weeks after initiation or dose increase | | Severity range | Comedonal to nodulocystic; most cases are mild-to-moderate | | First-line management | Benzoyl peroxide 2.5-5% wash or gel, salicylic acid 0.5-2% leave-on | | Second-line management | Topical tretinoin, topical clindamycin-benzoyl peroxide combination, oral doxycycline | | Escalation trigger | Nodules, cysts, scarring, or failure of 8-12 weeks of topical therapy | | Discontinuation threshold | Severe nodulocystic disease unresponsive to oral isotretinoin, or clinically unacceptable quality-of-life impact |

Why AndroGel Causes Acne: The Mechanism Matters for Treatment Choice

Exogenous testosterone delivered via AndroGel is converted peripherally to dihydrotestosterone (DHT) by 5-alpha reductase. DHT binds androgen receptors in sebaceous glands with roughly five times the affinity of testosterone, driving sebocyte proliferation and excess sebum production. That excess sebum, combined with follicular hyperkeratinization, creates the substrate for Cutibacterium acnes colonization and the subsequent inflammatory cascade. The FDA prescribing information for AndroGel 1% lists acne as an adverse reaction category under dermatologic effects, noting it occurred in approximately 3-8% of subjects across clinical studies.

Because the androgen stimulus is ongoing, treatment must address both the microenvironment (excess sebum, bacterial load, follicular keratin plugs) and, where possible, the downstream androgen signal. This is different from treating acne in a patient who is not on exogenous androgens, where the hormonal driver is variable and often addressable with combination oral contraceptives or spironolactone. In men on TRT, those hormonal options are not applicable, which narrows the toolkit and makes topical and oral retinoids more important endpoints in the treatment ladder.

OTC First-Line Agents: What to Use and How

Benzoyl Peroxide (BPO)

Benzoyl peroxide is the most evidence-backed OTC acne agent and an appropriate first step for new or mild AndroGel-related acne. It works by releasing free oxygen radicals that kill C. acnes without selecting for resistance, a meaningful advantage given the chronic nature of TRT-associated acne. The American Academy of Dermatology (AAD) acne guidelines recommend BPO as a core component of nearly every acne regimen because of this resistance-sparing property.

Dose and formulation: Start with 2.5% gel or wash. Concentrations above 5% increase irritation without meaningfully improving efficacy, according to comparative trial data published in the Journal of the American Academy of Dermatology. Apply once daily to affected areas; increase to twice daily if tolerated after two weeks. Wash formulations (used for 60-90 seconds then rinsed) reduce irritation on the trunk, which is a common acne site in TRT patients given application zones.

Key caution: BPO bleaches fabric. Counsel patients to let it dry fully before dressing, and to use white pillowcases.

Salicylic Acid

Salicylic acid (0.5-2%) is a beta-hydroxy acid that dissolves the intercellular bonds holding keratinocytes in the follicle, directly addressing the comedonal component. It is best suited for blackheads and whiteheads rather than inflammatory papules. The FDA OTC monograph for acne approves salicylic acid at 0.5-2% as a safe and effective acne treatment. Use it as a leave-on gel or toner once or twice daily. It can be combined with BPO (applied at different times of day) to address both comedonal and bacterial components simultaneously.

Adapalene 0.1% (OTC Differin)

Since 2016, adapalene 0.1% gel has been available over the counter in the United States. It is a third-generation retinoid that normalizes follicular keratinization and has anti-inflammatory effects through modulation of toll-like receptor signaling. A randomized controlled trial in the Journal of Drugs in Dermatology demonstrated significant reductions in both comedone and inflammatory lesion counts versus vehicle. For TRT-related acne, where follicular plugging is a primary driver, adapalene 0.1% is an unusually strong OTC option. Apply a pea-sized amount to the entire face (or affected area) at night, starting every other night to minimize initial irritation.

Prescription Second-Line Agents

Topical Combination Products: Clindamycin-Benzoyl Peroxide

Clindamycin phosphate 1% combined with benzoyl peroxide (available as Benzaclin, Duac, and generics) is a standard second-line prescription topical for inflammatory acne. Clindamycin suppresses C. acnes protein synthesis by binding the 50S ribosomal subunit; pairing it with BPO prevents the emergence of clindamycin-resistant strains. The AAD guidelines give this combination a Grade A recommendation for mild-to-moderate inflammatory acne. Apply once or twice daily to clean, dry skin. It is well-suited for the truncal and facial distribution common in androgen-driven acne.

Prescription-Strength Tretinoin (0.025%, 0.05%, 0.1%)

Tretinoin is the gold-standard topical retinoid and the natural next step when OTC adapalene 0.1% is insufficient. It binds retinoic acid receptors more broadly than adapalene, driving stronger normalization of follicular keratinization and significant sebum reduction via suppression of sebocyte differentiation. A meta-analysis in the British Journal of Dermatology confirmed that topical retinoids outperform vehicle across lesion types. Start at 0.025% cream or gel nightly; increase to 0.05% after 8-12 weeks if tolerated and response is inadequate. The 0.1% formulation is reserved for treatment-resistant cases because of irritation risk. Counsel patients on the retinoid purge (temporary worsening at weeks 2-6), sun sensitivity, and the need for daily SPF 30 or higher.

Interaction note: Tretinoin is physically and chemically inactivated when applied simultaneously with BPO. Apply tretinoin at night and BPO in the morning to avoid this interaction. This is a clinically significant point that published pharmacology data and the AAD both flag explicitly.

Oral Doxycycline (50-100 mg Daily)

When topical agents fail or when the acne is moderately severe at presentation (multiple inflammatory papules, early nodules), oral doxycycline is the preferred antibiotic. It suppresses C. acnes and has independent anti-inflammatory effects through inhibition of matrix metalloproteinases. The AAD guidelines recommend limiting oral antibiotic courses to 3-6 months and always combining them with BPO to prevent resistance. Subantimicrobial-dose doxycycline (40 mg modified-release, brand name Oracea) is an option for patients in whom antibiotic-resistance risk is a concern; clinical trial data in the Journal of the American Academy of Dermatology showed efficacy versus placebo for inflammatory lesions at this dose. Take with food to reduce GI upset; avoid taking within two hours of calcium-rich foods, antacids, or iron supplements, which chelate tetracyclines and reduce absorption.

Topical Ivermectin 1% (Soolantra)

Topical ivermectin, approved for rosacea, is used off-label in some acne cases for its anti-inflammatory and anti-parasitic (anti-Demodex) properties. Evidence in standard acne is limited, but for patients who cannot tolerate clindamycin combinations or who present with a rosacea-acne overlap, it is occasionally prescribed. Mention this option to your dermatologist if standard second-line therapies have been inadequate.

Third-Line and Escalation: Oral Isotretinoin

Oral isotretinoin (Accutane, Absorica, and generics) is the only agent that produces long-term remission in severe acne by causing permanent atrophy of sebaceous glands. Standard dosing targets a cumulative dose of 120-150 mg/kg, typically delivered as 0.5-1 mg/kg/day in two divided doses over 16-24 weeks. Sebum production drops by up to 90% during a course, according to mechanistic studies published in the Journal of Investigative Dermatology.

TRT-specific consideration: Isotretinoin reduces sebaceous gland output independently of circulating androgen levels. This means it can work even while AndroGel continues. However, because AndroGel maintains the hormonal stimulus, relapse rates after isotretinoin in TRT patients may be higher than in the general acne population. Some patients require a second course or maintenance with topical retinoids after completing isotretinoin.

Monitoring requirements under iPLEDGE: All isotretinoin prescriptions in the United States require enrollment in the FDA REMS program iPLEDGE. For male patients, monthly pregnancy tests are not required, but monthly lab monitoring (lipid panel, liver function tests, CBC) is standard practice, given isotretinoin's effects on triglycerides and hepatic enzymes. A clinical review in JAMA Dermatology recommends baseline fasting lipids before initiation, as isotretinoin commonly elevates triglycerides by 25-50%.

Drug interactions with isotretinoin: Avoid tetracycline-class antibiotics (including doxycycline) during isotretinoin therapy. The combination raises intracranial pressure and carries a risk of pseudotumor cerebri, as documented in the FDA prescribing information for isotretinoin. Do not combine isotretinoin with vitamin A supplements (additive toxicity). High-dose vitamin E supplementation should also be avoided.

Agents to Avoid or Use with Caution

Spironolactone: This aldosterone antagonist blocks androgen receptors and reduces sebaceous output. It is widely used for acne in females on hormonal contraception, but it causes gynecomastia, reduced libido, and can suppress the testosterone effect that TRT is prescribed to achieve. It is not appropriate for men on AndroGel unless TRT is being discontinued.

Oral contraceptives: Not applicable to male patients.

Topical corticosteroids: These are sometimes self-applied by patients who mistake acne for dermatitis. Topical steroids worsen acne by suppressing local immunity and promoting C. acnes overgrowth (steroid acne). Avoid them on acne-affected skin.

Minocycline: Though a tetracycline-class antibiotic used in acne, a Cochrane review found no evidence of superior efficacy over doxycycline, and minocycline carries higher risks (autoimmune hepatitis, drug-induced lupus, vestibular side effects, blue-black skin pigmentation with prolonged use). Doxycycline is preferred.

When to Escalate and When to Consider Pausing TRT

If nodulocystic lesions appear, if scarring has begun, or if 12 weeks of combined topical therapy has produced no meaningful response, escalation to oral isotretinoin with dermatology involvement is appropriate. A clinical consensus statement from the American Acne and Rosacea Society supports early escalation in scarring-prone patients to prevent permanent disfigurement.

In cases where isotretinoin is contraindicated or refused, a temporary dose reduction of AndroGel (with endocrinology input to maintain therapeutic testosterone levels) may reduce sebaceous stimulation enough to allow topical agents to work. Stopping AndroGel entirely resolves androgen-driven acne in most patients, but that decision requires weighing the benefits of TRT against dermatologic impact, and should never be made without prescriber involvement.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• AndroGel 1% (testosterone gel) FDA Prescribing Information, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021015s040lbl.pdf
• Zaenglein AL, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. 2016;74(5):945-973. https://www.jaad.org/article/S0190-9622(15)02614-6/fulltext
• Isotretinoin FDA Prescribing Information (Absorica), 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018662s059lbl.pdf
• iPLEDGE REMS Program. https://www.ipledgeprogram.com/
• Cunliffe WJ, et al. Comedone formation: etiology, clinical presentation, and treatment. British Journal of Dermatology. Meta-analysis. https://onlinelibrary.wiley.com/doi/10.1111/bjd.13462
• Shalita AR, et al. Benzoyl peroxide concentration comparisons in acne treatment. Journal of the American Academy of Dermatology. 2010. https://www.jaad.org/article/S0190-9622(10)00329-8/fulltext
• Strauss JS, et al. Isotretinoin: mechanism and cumulative dosing. JAMA Dermatology. 2017. https://jamanetwork.com/journals/jamadermatology/fullarticle/2546803
• Webster GF. Subantimicrobial-dose doxycycline in acne. Journal of the American Academy of Dermatology. 2005. https://www.jaad.org/article/S0190-9622(05)23729-3/fulltext
• Garner SE, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database of Systematic Reviews. 2012. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002086.pub2/full
• Leyden JJ, et al. Adapalene 0.1% gel for acne vulgaris: RCT. Journal of Drugs in Dermatology. https://jddonline.com/articles/adapalene-gel-01-for-acne-vulgaris-a-randomized-controlled-trial/
• Tretinoin and BPO inactivation pharmacology. National Library of Medicine. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923954/
• Thiboutot DM, et al. Sebaceous gland activity and isotretinoin. Journal of Investigative Dermatology. https://www.jidonline.org/article/S0022-202X(15)52124-8/fulltext
• Rao J, et al. American Acne and Rosacea Society consensus on scarring acne. NLM. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445894/
• Isotretinoin pharmacology and dosing. StatPearls, National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK537171/
• FDA OTC Acne Drug Products Monograph. Federal Register. 2019. https://www.federalregister.gov/documents/2019/03/04/2019-03295/skin-protectant-drug-products-for-over-the-counter-human-use